Kate Rawson is a senior editor at Prevision Policy LLC, a continuous information service based in Georgetown in Washington, D.C. She has more than 20 years of experience covering U.S. Food and Drug Administration (FDA)-regulated health care industries, primarily pharmaceuticals and biotechnology. She writes frequently about health care policy, FDA regulatory policy, and coverage and reimbursement. In addition to her work at Prevision Policy, she contributes to “The Pink Sheet” and The RPM Report, both Informa Pharma Intelligence publications. Recent coverage includes FDA advisory committee meetings, the Trump Administration transition, patient-focused drug development, drug pricing, “21st Century Cures,” and biosimilars.
She co-founded the FDA/CMS Summit for Biopharmaceutical Executives, and more recently, the Biopharma Congress. Both are annual conferences in Washington, D.C. Previously, she was a senior editor for “The Pink Sheet,” published by FDC Reports. During her ten-year tenure at FDC Reports, she helped launch “The Pink Sheet” DAILY, and served as managing editor of “The Rose Sheet,” which covers regulatory and business news of the cosmetics industry.
